Search
Close this search box.
Search
Close this search box.

Pakistan

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time

Axi Attends Jeddah Fintech Week 2025, Showcases Their Products and Services

SYDNEY, Dec. 04, 2025 (GLOBE NEWSWIRE) — Axi, a financial leader in online CFD and FX trading, participated in Jeddah Fintech Week 2025, held on November 16-17, at the Hilton Jeddah in Saudi Arabia. Attendees had the opportunity to learn more about the Axi brand and its products and latest